Pricing Log in Create free account
Friday 6 November 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

58.23 0.77 +1.34%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Arrowhead Pharmaceuticals, Inc. (ARWR) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a P/B ratio of 17.7×. Over the past ten years it has ranged from 0.8× (December 2016) to 47.9× (January 2025); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 9.2× (24.54%)
FY2024 12.1× 24.45%
FY2023 9.8× 17.16%
FY2022 8.3× (47.43%)
FY2021 15.8× 68.68%
FY2020 9.4× (13.34%)
FY2019 10.8× (35.75%)
FY2018 16.9× 314.84%
FY2017 4.1× (13.88%)
FY2016 4.7× 56.69%

Quarterly newest first

Period P/B ratio Change
Jun 2026 25.1× 68.19%
Mar 2026 14.9× (7.79%)
Dec 2025 16.2× 76.44%
Sep 2025 9.2× 116.84%
39 more quarters

Against its own ten years

Low 0.8× High 47.9×
Ten-year median 8.8×
Current reading's percentile 87

P/B ratio against peers

Company P/B ratio
CYTK Cytokinetics, Incorporated compare n/m
KRYS Krystal Biotech, Inc. compare 6.2×
CORT Corcept Therapeutics Incorporated compare 9.2×
SYRE Spyre Therapeutics, Inc. compare 9.5×
PTGX Protagonist Therapeutics, Inc. compare 10.6×
CAI Caris Life Sciences,�Inc. compare 12.7×
TWST Twist Bioscience Corporation compare 17.1×
ARWR Arrowhead Pharmaceuticals, Inc. 17.7×
MDGL Madrigal Pharmaceuticals, Inc. compare 18.7×
Biotechnology industry median 2.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on ARWR